AstraZeneca will list its ordinary shares directly on the New York Stock Exchange on Monday, marking a strategic shift from its American depositary receipt program. By securing a primary listing in the United States—its largest market, accounting for over 40% of group revenues—the company aims to broaden its investor base, enhance share liquidity and address pricing pressures in the U.S. pharmaceutical sector. This move follows AstraZeneca’s announcement in 2025 to end its ADR program, and it underscores management’s commitment to aligning capital markets strategy with commercial priorities in North America.

In a separate announcement last Thursday, AstraZeneca pledged to invest $15 billion in China over the next five years to bolster local manufacturing capacity and research & development capabilities. These funds will support the construction of two advanced biologics production facilities in Shanghai and Suzhou, expand clinical trial sites across 10 Chinese provinces and fund over 200 early-stage discovery collaborations with domestic biotech firms. The investment coincides with the first visit by a British prime minister to Beijing in eight years, signaling strong government support for deeper UK–China life sciences ties.

AstraZeneca has entered into a collaboration with Hong Kong–listed CSPC Pharmaceuticals to co-develop eight obesity and type 2 diabetes programs, including one clinical-ready once-monthly injectable and three preclinical assets. The agreement provides CSPC with $1.2 billion in upfront payments and up to $17.3 billion in contingent payments tied to regulatory approvals, R&D milestones and global sales thresholds. AstraZeneca will assume exclusive commercialization rights outside Greater China following Phase I completion, while CSPC retains rights in China, Hong Kong, Macau and Taiwan, with an option for co-commercialization post-approval.

With several blockbuster drugs facing patent expiry by 2027, AstraZeneca is balancing its U.S. listing and China investment to secure two key growth engines. Analysts estimate that biologics manufacturing in China could contribute up to 15% of the group’s supply chain capacity by 2030, while the obesity pipeline collaboration could add $6–8 billion in peak annual sales if late-stage trials succeed. Portfolio manager Camilla Oxhamre has highlighted that the combined U.S. and China focus will be “pivotal to offset patent expiries in oncology and cardiovascular franchises” over the next five years.